HMGB1 is a new immunological biomarker for prognosis in patients with digestive cancer.

HMGB1 是一种用于消化道癌症患者预后的新型免疫生物标志物。

• 批准号: 23591963
• 负责人: SUZUKI Nobuaki
• 金额: $ 3.08万
• 依托单位: Yamaguchi University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591963/
• 关键词: HMGB1; バイオマーカー; NKG2D; ULBP1; B7-H3; NKG2DL; Toll like receptor; 化学療法; 免疫療法; Toll like recepter

High mobility group box 1 (HMGB1) plays a role in many clinical conditions such as autoimmunity, acute ischemia-reperfusion injury, cardiovascular disease and cancer. HMGB1 is a nuclear protein and released from the apoptotic cells to activate cytotoxic T cells and antigen-presenting cells effectively. The aim of this study was to clarify HMGB1 is associated with recurrence or prognosis as a biomarker, and we performed immunohistochemistry of HMGB1 in resected specimen. We performed immunohistochemistry for 90 gastric cancer cases, 30 cases of colorectal cancer, and 10 cases as pancreatic cancer, the expression of HMGB1 in cancer tissues is a good prognostic factor in gastric cancer patients. B7-H3, NKG2D, NKG2DL are also stained, with a combination of expression of staining intensity, ULBP1/NKG2D interaction was suggested as good prognostic marker for the patients in gastric cancer.

高迁移率族蛋白1（HMGB 1）在自身免疫、急性缺血再灌注损伤、心血管疾病和癌症等临床疾病中发挥重要作用。HMGB 1是一种核蛋白，从凋亡细胞中释放出来，有效地激活细胞毒性T细胞和抗原呈递细胞。本研究的目的是阐明HMGB 1作为一种生物标志物与复发或预后相关，我们对切除标本进行了HMGB 1的免疫组化。我们对90例胃癌、30例结直肠癌和10例胰腺癌进行了免疫组化检测，发现HMGB 1在胃癌组织中的表达是判断胃癌患者预后的一个良好指标。B7-H3、NKG 2D、NKG 2DL也被染色，结合染色强度的表达，ULBP 1/NKG 2D相互作用被认为是胃癌患者的良好预后标志。